Sneha Rochlani

Sneha Rochlani

Auto-generated profile, based on publicly available information

Sneha Rochlani

Department of Pharmaceutical Chemistry, Bharati Vidyapeeth’s College of Pharmacy, Kolhapur, India

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2023 in Natural Product Research
Verified
Journal Article
Closed access
SRSneha Rochlani
Sneha Rochlani
MBManish Bhatia
Manish Bhatia
SRSanket Rathod
Sanket Rathod
PCPrafulla Choudhari
Prafulla Choudhari
RDRakesh Dhavale
Rakesh Dhavale
Limonoids serve as vital secondary metabolites. Citrus limonoids show a wide range of pharmacological potential. As a result of which limonoids from citrus are of considerable research interest. Identification of new therapeutic molecules from natural origins has been widely adopted as a successful strategy in drug discovery. This work mainly focused on the high-throughput computational exploration of the antiviral potential of three vital limonoids, i.e. Obacunone, Limonin and Nomilin against spike proteins of SARS CoV-2 (PDB:6LZG), Zika virus NS3 helicase (PDB:5JMT), Serotype 2 RNA dependent RNA polymerase of dengue virus (PDB:5K5M). Herein we report the molecular docking, MD simulation studies of nine docked complexes, and density functional theory (DFT) of selected limonoids. The results of this study indicated that all three limonoids have good molecular features but out of these three obacunone exerted satisfactory results for DFT, docking and MD simulation study. Graphical Abstract

27 March 2023 in Journal of Molecular Modeling
Verified
Journal Article
Closed access
PDF file
SRSanket Rathod
Sanket Rathod
PCPooja Chavan
Pooja Chavan
DMDeepak Mahuli
Deepak Mahuli
SRSneha Rochlani
Sneha Rochlani
SSShalini Shinde
Shalini Shinde
FTFiroj A. Tamboli
Firoj A. Tamboli

5 April 2025 in Journal of Molecular Structure
Verified
Journal Article
Closed access
AGAkshay Gurav
Akshay Gurav
LBLalit Bhosale
Lalit Bhosale
PCPrakash N. Chavan
Prakash N. Chavan
RGRutikesh Gurav
Rutikesh Gurav
NNNisha Nerlekar
Nisha Nerlekar
SHShankar Hangirgekar
Shankar Hangirgekar

24 January 2024 in Journal of Biomolecular Structure and Dynamics
Verified
Journal Article
Closed access
SRSanket Rathod
Sanket Rathod
SDSreenath Dey
Sreenath Dey
PCPrafulla Choudhari
Prafulla Choudhari
DMDeepak Mahuli
Deepak Mahuli
SRSneha Rochlani
Sneha Rochlani
RERajakumara Eerappa
Rajakumara Eerappa
Antibiotic resistance is a pressing global health challenge, driven in part by the remarkable efflux capabilities of efflux pump in AcrB (Acriflavine Resistance Protein B) protein in Gram-negative bacteria. In this study, a multi-approached computational screening strategy encompassing molecular docking, In silico absorption, distribution, metabolism, excretion and toxicity (ADMET) analysis, druglikeness assessment, molecular dynamics simulations and density functional theory studies was employed to identify novel hits capable of acting against AcrB-mediated antibiotic resistance. Ligand library was acquired from the COCONUT database. Performed computational analyses unveiled four promising hit molecules (CNP0298667, CNP0399927, CNP0321542 and CNP0269513). Notably, CNP0298667 exhibited the highest negative binding affinity of -11.5 kcal/mol, indicating a possibility of strong potential to disrupt AcrB function. Importantly, all four hits met stringent druglikeness criteria and demonstrated favorable in silico ADMET profiles, underscoring their potential for further development. MD simulations over 100 ns revealed that the CNP0321542-4DX5 and CNP0269513-4DX5 complexes formed robust and stable interactions with the AcrB efflux pump. The identified hits represent a promising starting point for the design and optimization of novel therapeutics aimed at combating AcrB-mediated antibiotic resistance in Gram-negative bacteria.Communicated by Ramaswamy H. Sarma.

9 November 2025 in Journal of Molecular Structure
Verified
Journal Article
Closed access
SLShyam V. Londhe
Shyam V. Londhe
SSShubham M. Sulakhe
Shubham M. Sulakhe
SPShriram B. Pawar
Shriram B. Pawar
AKAbhishek K. Khanzode
Abhishek K. Khanzode
SSSomesh S. Salunke
Somesh S. Salunke
KHKishan P. Haval
Kishan P. Haval

25 February 2021 in Current Computer-Aided Drug Design
Verified
Journal Article
Closed access
PDF file
SRSneha P. Rochlani
Sneha P. Rochlani
LDLalita K. Dahiwade
Lalita K. Dahiwade
PCPrafulla B. Choudhari
Prafulla B. Choudhari
Background: Cancer is the leading cause of death in the current decade. With the advancement in scientific technologies various treatments had been introduced but they suffer from numerous side effects. The root cause of cancer is alteration in the cell cycle which generates cancerous cells. Development of new lead which specifically target cancerous cells is needed to reduce the side effect and to overcome multidrug resistance. Objective: Design and development of anticancer leads targeting colchicine site of microtubules using structurally screened phytofragments is the primary objective of this work. Material and methods: Bioactive fragments of phytoconstituents were identified from a large dataset of phytochemicals. The identified phytofragments were used to design structures which were screened for virtual interactions with colchicine site of microtubules. Selected set of designed molecules was further screened for drug like properties and toxicity. The designed molecules which surpassed virtual filters were then synthesized, characterized and further screened for anticancer potential against HEPG2 liver cancer cellline. Result: A novel series of chalcones was designed by phytofragment based drug design. The synthesized compounds showed profound anticancer activity comparable to standard, 5-fluoro uracil. In the present communication, rational development of anticancer leads targeting colchicine site of microtubules has been done by integrating pocket modeling and virtual screening with synthesis and biological screening. Conclusion: In this present work, we found that compound S4 and S3 showed specific interaction with colchicine site of microtubules and desirable anticancer activity. Further optimization of the lead could yield drug like candidate with reduced side effects and may overcome multidrug resistance.